Skip to main content
. 2011 Mar 14;102(6):1171–1175. doi: 10.1111/j.1349-7006.2011.01909.x

Table 2.

 Best overall response to paclitaxel, ifosfamide, and nedaplatin as second‐line chemotherapy regimen in 45 patients with metastatic urothelial carcinoma

Response No. of patients (%)
CR 2 (4.4)
PR 16 (35.6)
SD 15 (33.3)
PD 12 (26.7)
Total 45 (100)

CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.